14,647 results match your criteria Cholangiocarcinoma


Intrahepatic mucinous cholangiocarcinoma.

Kaohsiung J Med Sci 2020 Jun 3. Epub 2020 Jun 3.

Department of Medical Imaging, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/kjm2.12242DOI Listing

Advanced laparoscopic HPB surgery: Experience in Seoul National University Bundang Hospital.

Ann Gastroenterol Surg 2020 May 25;4(3):224-228. Epub 2020 Mar 25.

Seoul National University Bundang Hospital Gyeonggi-do Korea.

The worldwide trend in surgery has moved from open surgery to minimally invasive surgery. Likewise, the application of minimally invasive surgery in the hepato-pancreato-biliary (HBP) field is also rapidly expanding. The field of HBP surgery can be divided into liver, pancreas and biliary fields. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ags3.12323DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240149PMC

Loss of c-Jun N-terminal Kinase 1 and 2 Function in Liver Epithelial Cells Triggers Biliary Hyperproliferation Resembling Cholangiocarcinoma.

Hepatol Commun 2020 Jun 16;4(6):834-851. Epub 2020 Apr 16.

Department of Internal Medicine III University Hospital RWTH Aachen Aachen Germany.

Targeted inhibition of the c-Jun N-terminal kinases (JNKs) has shown therapeutic potential in intrahepatic cholangiocarcinoma (CCA)-related tumorigenesis. However, the cell-type-specific role and mechanisms triggered by JNK in liver parenchymal cells during CCA remain largely unknown. Here, we aimed to investigate the relevance of JNK1 and JNK2 function in hepatocytes in two different models of experimental carcinogenesis, the dethylnitrosamine (DEN) model and in nuclear factor kappa B essential modulator (NEMO) mice, focusing on liver damage, cell death, compensatory proliferation, fibrogenesis, and tumor development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep4.1495DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262317PMC

Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres for treatment of unresectable intrahepatic cholangiocarcinoma.

J Cancer 2020 18;11(15):4534-4541. Epub 2020 May 18.

Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China.

: This study aimed to evaluate the efficacy and safety of doxorubicin-loaded drug-eluting beads transarterial chemoembolization (DEB-TACE) with CalliSpheres microspheres (CSM) in treating unresectable intrahepatic cholangiocarcinoma (ICC). : 88 unresectable ICC patients who received DEB-TACE treatment with CSM were retrospectively enrolled in this study. Information about treatment response, survival and adverse events were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.39410DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255354PMC

Intraluminal Brachytherapy in Unresectable Extrahepatic Biliary Duct Cancer: An Italian Pooled Analysis.

Anticancer Res 2020 Jun;40(6):3417-3421

Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, UOC Radioterapia Oncologica, Rome, Italy.

Background/aim: To evaluate the outcome of patients with unresectable extrahepatic cholangiocarcinoma (CC) treated with external-beam radiotherapy (EBRT) and concurrent chemotherapy (CT) with or without intraluminal brachytherapy (ILBT) boost or with definitive ILBT.

Patients And Methods: A pooled analysis of patients with non-metastatic unresectable CC was performed. They were treated in three different institution with EBRT plus CT with or without an ILBT boost. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14326DOI Listing

Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow.

Anticancer Res 2020 Jun;40(6):3013-3030

Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.

Biliary tract cancer (BTC) patients usually have poor prognosis. Whereas combination chemotherapy has been shown to improve survival in the frontline setting, second-line treatment is subject to a lot of debate in the scientific community. Recent data of the ABC-06 trial has provided slight evidence for the use of second-line chemotherapy after progression on cisplatin plus gemcitabine combination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14282DOI Listing

A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma.

Cancers (Basel) 2020 May 31;12(6). Epub 2020 May 31.

Experimental Hepatology and Drug Targeting (HEVEFARM) Group, University of Salamanca, Biomedical Research Institute of Salamanca (IBSAL), 37007 Salamanca, Spain.

The diagnosis of adenocarcinomas located in the pancreas head, i.e., distal cholangiocarcinoma (dCCA) and pancreatic ductal adenocarcinoma (PDAC), constitutes a clinical challenge because they share many symptoms, are not easily distinguishable using imaging techniques and accurate biomarkers are not available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061433DOI Listing

An Immune-Magnetophoretic Device for the Selective and Precise Enrichment of Circulating Tumor Cells from Whole Blood.

Micromachines (Basel) 2020 May 30;11(6). Epub 2020 May 30.

Laboratory of Molecular Pathology and Cancer Genomics, College of Pharmacy and Research Institute of Pharmaceutical Science, Seoul National University, Seoul 08826, Korea.

Here, we validated the clinical utility of our previously developed microfluidic device, GenoCTC, which is based on bottom magnetophoresis, for the isolation of circulating tumor cells (CTCs) from patient whole blood. GenoCTC allowed 90% purity, 77% separation rate, and 80% recovery of circulating tumor cells at a 90 μL/min flow rate when tested on blood spiked with epithelial cell adhesion molecule (EpCAM)-positive Michigan Cancer Foundation-7 (MCF7) cells. Clinical studies were performed using blood samples from non-small cell lung cancer (NSCLC) patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/mi11060560DOI Listing

Targeting Wnt Signaling for the Treatment of Gastric Cancer.

Int J Mol Sci 2020 May 30;21(11). Epub 2020 May 30.

The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne VIC 3000, Australia.

The Wnt signaling pathway is evolutionarily conserved, regulating both embryonic development and maintaining adult tissue homeostasis. Wnt signaling controls several fundamental cell functions, including proliferation, differentiation, migration, and stemness. It therefore plays an important role in the epithelial homeostasis and regeneration of the gastrointestinal tract. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21113927DOI Listing

[A probable fatal argon gas embolism during resection of a cutaneous biliary fistula - a case report].

Authors:
Karlyn Powell

Rev Bras Anestesiol 2020 May 29. Epub 2020 May 29.

Baylor College of Medicine, Department of Anesthesiology, Houston, Texas, USA. Electronic address:

Background: The Argon Beam Coagulator (ABC) achieves hemostasis but has potential complications in the form of argon gas embolisms. Risk factors for embolisms have been identified and ABC manufacturers have developed guidelines for usage of the device to prevent embolism development.

Case Report: A 49 year-old male with history of recurrent cholangiocarcinoma status post resection presented for resection of a cutaneous biliary fistula. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bjan.2019.12.016DOI Listing

Intrahepatic Cholangiocarcinoma in a Patient with Hepatitis C: A Cautionary Tale.

R I Med J (2013) 2020 Jun 1;103(5):30-34. Epub 2020 Jun 1.

CODAC Behavioral Health and University of Rhode Island, Providence, RI.

View Article

Download full-text PDF

Source

Stigmasterol Causes Ovarian Cancer Cell Apoptosis by Inducing Endoplasmic Reticulum and Mitochondrial Dysfunction.

Pharmaceutics 2020 May 28;12(6). Epub 2020 May 28.

Department of Food and Nutrition, College of Science and Technology, Kookmin University, Seoul 02707, Korea.

Background: Phytosterols have physiological effects and are used as medicines or food supplements. Stigmasterol has shown anticancer effects against various cancers such as hepatoma, cholangiocarcinoma, gall bladder carcinoma, endometrial adenocarcinoma and skin, gastric, breast, prostate, and cervical cancer. However, there are no reports on stigmasterol's effects on ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/pharmaceutics12060488DOI Listing

The methods of preoperative biliary drainage for resectable hilar cholangiocarcinoma patients: A protocol for systematic review and meta analysis.

Medicine (Baltimore) 2020 May;99(21):e20237

Department of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, Jiangsu Province.

Objectives: To compare the clinical outcomes of endoscopic biliary drainage (EBD) with those of percutaneous transhepatic biliary drainage (PTBD) in patients with resectable hilar cholangiocarcinoma (HCCA) and evaluate the effect of EBD and PTBD on tumor prognosis.

Materials And Methods: PubMed, EMBASE, and Cochrane Library databases were searched for articles about the comparison between PTBD and EBD. Data were analyzed by Revman 5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020237DOI Listing

Thymidine phosphorylase promotes angiogenesis and tumour growth in intrahepatic cholangiocarcinoma.

Cell Biochem Funct 2020 May 31. Epub 2020 May 31.

Department of Gastroenterology, Shandong Provincial Qianfoshan Hospital, The First Hospital Affiliated with Shandong First Medical University, Jinan, People's Republic of China.

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer, and thymidine phosphorylase (TP) is a regulator of angiogenesis. To investigate the biological activities of TP in ICC, we established human cholangiocarcinoma RBE cell lines overexpressing TP or silencing TP. Overexpression of TP enhanced viability, suppressed apoptosis and increased tube formation in human umbilical vein endothelial cells, while downregulation of TP reversed these effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cbf.3541DOI Listing

Three-dimensional analysis of extrahepatic cholangiocarcinoma and tumor budding.

J Pathol 2020 Jun 1. Epub 2020 Jun 1.

Department of Pathology, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland, United States.

Advances in tissue clearing and microscopy make it possible to study human diseases in 3-dimensions (3-D). High-grade tumor budding (TB) is known to be associated with poor prognosis in various cancers; however, little is known about the 3-D architecture of TB. Using tissue clearing, we analyzed the 3-D structure of TB and E-cadherin expression in 31 extrahepatic cholangiocarcinomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.5474DOI Listing

Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis.

Lipids Health Dis 2020 May 31;19(1):118. Epub 2020 May 31.

Digestive Disease Key Laboratory of Qingdao, Qingdao, 266071, China.

Background: NAFLD is tightly associated with various diseases such as diabetes, cardiovascular disease, kidney disease, and cancer. Previous studies had investigated the association between NAFLD and various extrahepatic cancers, but the available data to date is not conclusive. The aim of this study was to investigate the association between NAFLD and various extrahepatic cancers comprehensively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12944-020-01288-6DOI Listing

Comparison of Waitlist Mortality Between Cholangiocarcinoma and Hepatocellular Carcinoma Liver Transplant Candidates.

Liver Transpl 2020 May 31. Epub 2020 May 31.

Department of Surgery, Division of Hepatobiliary Surgery and Liver Transplantation, Vanderbilt University Medical Center, Nashville, TN, USA.

Background: Despite the divergent disease biology of cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC), waitlist prioritization is identical for both diagnoses.

Methods: We compared waitlist and post-transplant outcomes between CCA and HCC liver transplant patients with MELD exceptions using Scientific Registry of Transplant Recipients data. 408 CCA candidates listed between 2003 and mid-2017 were matched to two HCC cohorts by: listing date (±2 months, n=816), and OPTN region and date (±6 months, n=408). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/lt.25807DOI Listing

Personalized Preoperative Nomograms Predicting Postoperative Risks after Resection of Perihilar Cholangiocarcinoma.

World J Surg 2020 May 30. Epub 2020 May 30.

Department of Surgery, Assistance Publique Hôpitaux de Paris, Paul-Brousse Hospital, Centre Hépato-Biliaire, 94800, Villejuif, France.

Introduction: Curative treatment of perihilar tumors requires major hepatectomy responsible for high morbidity and mortality. Current nomograms are based on definitive pathological analysis, not usable for patient selection. Our aim was to propose preoperative predictors for severe morbidity (Dindo-Clavien ≥3) and mortality at sixth month after resection of perihilar tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00268-020-05618-8DOI Listing

Analysis of treatment methods and prognostic factors in 354 cases of hilar cholangiocarcinoma: A cohort study.

J Cancer Res Ther 2020 ;16(2):230-237

Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.

Context: Better management strategies are needed to improve the survival of patients with hilar cholangiocarcinoma (HCCA).

Aims: This study was designed to examine the effects of different treatment methods on survival and prognostic factors in HCCA.

Settings And Design: We retrospectively analyzed the clinical data of 354 patients with HCCA treated at our institution from 2003 to 2013. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcrt.JCRT_637_19DOI Listing
January 2020

Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis.

J Vasc Interv Radiol 2020 May 27. Epub 2020 May 27.

Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Room E.01.1.29, Internal Mail E01.132, P.O. 85500, 3508 GA Utrecht, The Netherlands. Electronic address:

Purpose: To report outcomes of yttrium-90 (Y) radioembolization in patients with unresectable intrahepatic cholangiocarcinoma (ICC).

Materials And Methods: Retrospective review was performed of 115 patients at 6 tertiary care centers; 92 were treated with resin microspheres (80%), 22 were treated with glass microspheres (19%), and 1 was treated with both. Postintervention outcomes were compared between groups with χ tests. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jvir.2020.02.008DOI Listing

Current status of liver transplantation in North America.

Int J Surg 2020 May 27. Epub 2020 May 27.

Department of Surgery, University of Cincinnati College of Medicine, USA. Electronic address:

Liver transplantation is continuing to grow and evolve in North America. Changes in organ availability, recipient selection, indications and progressive approaches to oncologic treatment have occurred in the last five years. Despite increased activity in deceased and living donation in North America, there continues to be a high mortality on the waitlist as the recipient indications have changed over time which has led to new approaches to help patients with end-stage liver disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijsu.2020.05.059DOI Listing

Downstaging with Radioembolization or Chemotherapy for Initially Unresectable Intrahepatic Cholangiocarcinoma.

Ann Surg Oncol 2020 May 29. Epub 2020 May 29.

Departement of Medical Oncology, Centre Eugène Marquis, Rennes, France.

Objective: The aim of this retrospective study was to compare the outcomes of patients resected for intrahepatic cholangiocarcinoma (ICC) with upfront surgery or after downstaging treatment.

Methods: All consecutive patients with ICC between January 1997 and November 2017 were included in a single-center database and retrospectively reviewed. Patients were divided into two groups: upfront resection or resection after downstaging using either chemotherapy alone or selective internal radiation therapy (SIRT) combined with chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-020-08486-7DOI Listing

Pemigatinib: First Approval.

Authors:
Sheridan M Hoy

Drugs 2020 May 29. Epub 2020 May 29.

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Pemigatinib (PEMAZYRE™), a small molecule inhibitor of fibroblast growth factor receptor (FGFR) 1, FGFR2 and FGFR3, received accelerated approval in April 2020 in the USA for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma and a FGFR2 fusion or other rearrangement, as detected by a US FDA-approved test. Developed by Incyte Corporation, it is the first targeted treatment for cholangiocarcinoma in the USA. The recommended dosage of pemigatinib is 13. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-020-01330-yDOI Listing

CD105 is a prognostic marker and valid endothelial target for microbubble platforms in cholangiocarcinoma.

Cell Oncol (Dordr) 2020 May 28. Epub 2020 May 28.

Leeds Institute of Medical Research, St James's University Hospital, Leeds, LS9 7TF, UK.

Purpose: The current treatment outcomes in cholangiocarcinoma are poor with cure afforded only by surgical extirpation. The efficacy of targeting the tumoural endothelial marker CD105 in cholangiocarcinoma, as a basis for potential microbubble-based treatment, is unknown and was explored here.

Methods: Tissue expression of CD105 was quantified using immunohistochemistry in 54 perihilar cholangiocarcinoma samples from patients who underwent resection in a single centre over a ten-year period, and analysed against clinicopathological data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13402-020-00530-8DOI Listing

Targeting cancer stem cells in cholangiocarcinoma (Review).

Int J Oncol 2020 May 28. Epub 2020 May 28.

Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA.

The incidence of cholangiocarcinoma has been increasing steadily over the past 50 years, but the survival rates remained low due to the disease being highly resistant to non‑surgical treatment interventions. Cancer stem cell markers are expressed in cholangiocarcinoma, suggesting that they serve a significant role in the physiology of the disease. Cancer stem cells are frequently implicated in tumor relapse and acquired resistance to a number of therapeutic strategies, including chemotherapy, radiation and immune checkpoint inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2020.5074DOI Listing

Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials.

Crit Rev Oncol Hematol 2020 Apr 27;151:102975. Epub 2020 Apr 27.

Amsterdam UMC, Dept. of Medical Oncology, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands. Electronic address:

Patients with biliary tract cancer (BTC) have a high recurrence rate after complete surgical resection. To reduce the risk of recurrence and to improve survival, several chemotherapeutic agents that have shown to be active in locally advanced and metastatic BTC have been investigated in the adjuvant setting in prospective clinical trials. Based on the results of the BILCAP phase III trial, capecitabine was adapted as the standard of care by the ASCO clinical practice guideline. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2020.102975DOI Listing

Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: a randomized, double-blind, phase 2 trial - REACHIN.

Ann Oncol 2020 May 25. Epub 2020 May 25.

GE and Digestive Oncology Department, CUB Hôpital Erasme, Brussels, Belgium.

Background: There is a high unmet clinical need for treatments for advanced/metastatic biliary tract cancers (BTC) after progression on first-line chemotherapy. Regorafenib has demonstrated efficacy in some gastrointestinal tumors that progress on standard therapies.

Patients And Methods: REACHIN was a multicenter, double-blind, placebo-controlled, randomized phase 2 study designed to evaluate the safety and efficacy of regorafenib in patients with nonresectable/metastatic BTC that progressed after gemcitabine/platinum chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.018DOI Listing

Multicentre, Phase II Study of Gemcitabine and S-1 in Patients with Advanced Biliary Tract Cancer: TG1308 Study.

Liver Int 2020 May 28. Epub 2020 May 28.

National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.

Background & Aims: Gemcitabine plus cisplatin (GC) remains the standard, frontline therapy for advanced biliary tract cancer (ABTC). The JCOG1113 study suggested that the median overall survival and incidence of significant neutropenia after gemcitabine plus S-1 (GS) and GC treatments were comparable. This study evaluates the efficacy and safety of the modified GS regimen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14538DOI Listing

Difference in driver gene expression patterns between perihilar and peripheral intrahepatic cholangiocarcinoma in an experimental mouse model.

J Hepatobiliary Pancreat Sci 2020 May 28. Epub 2020 May 28.

Department of Surgery, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.

Background: The prognosis of intrahepatic cholangiocarcinoma (ICC) is based on tumor localization; however, the mechanism remains unknown. Therefore, we investigated the biological characteristics of perihilar and peripheral ICC in a mouse model.

Methods: The model was established by the administration of three oncogenic plasmids harboring myristoylated AKT, mutated human YAP, and pCMV-Sleeping Beauty into the mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jhbp.772DOI Listing

Roles of trained immunity in the pathogenesis of cholangiopathies: a novel therapeutic target.

Hepatology 2020 May 28. Epub 2020 May 28.

Jiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogenic Biology and Immunology, Laboratory of Infection and Immunity, Xuzhou Medical University, Xuzhou, People's Republic of China.

Cholangiopathies are a group of diseases mainly including primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), biliary atresia (BA), and cholangiocarcinoma (CCA). Very limited treatment options are available for these diseases. Following an injury and exposure to DAMPs (Damage associated molecular patterns) and/or PAMPs (Pathogen-associated molecular patterns), cholangiocytes produce a variety of pro-inflammatory cytokines/chemokines leading to the activation of other innate and also adaptive immune cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.31395DOI Listing

Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma.

Radiol Oncol 2020 May 28;54(2):149-158. Epub 2020 May 28.

Radiology Division, "Istituto Nazionale Tumori IRCCS Fondazione Pascale - IRCCS di Napoli", Naples, Italy.

Background The aim of the study was to investigate the performance of the Liver Imaging Reporting and Data System (LI-RADS) v2018 for combined hepatocellular-cholangiocarcinoma (cHCC-CCA) identifying the features that allow an accurate characterization. Patients and methods Sixty-two patients (median age, 63 years; range, 38-80 years), with pre-surgical biopsy diagnosis of hepatocellular carcinoma (HCC) that underwent hepatic resection, comprised our retrospective study. All patients were subject to multidetector computed tomography (MDCT); 23 patients underwent to magnetic resonance (MR) study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2478/raon-2020-0029DOI Listing

Vascular resection and reconstruction in hilar cholangiocarcinoma.

ANZ J Surg 2020 May 26. Epub 2020 May 26.

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong, Hong Kong, China.

Background: The aggressive approach of vascular resection plus reconstruction in curative resection of hilar cholangiocarcinoma (HC) remains controversial. This retrospective study investigated its short- and long-term outcomes.

Methods: Data of HC patients from 1989 to 2016 were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ans.15969DOI Listing

ASO Author Reflections: Laparoscopic Surgery of Perihilar Cholangiocarcinoma Between Oncologic Adequacy and Technical Challenges.

Ann Surg Oncol 2020 May 26. Epub 2020 May 26.

Hepatobiliary Surgery Division, Ospedale San Raffaele, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-020-08660-xDOI Listing

Technical Insights on Laparoscopic Left and Right Hepatectomy for Perihilar Cholangiocarcinoma.

Ann Surg Oncol 2020 May 26. Epub 2020 May 26.

Hepatobiliary Surgery Division, Ospedale San Raffaele, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-020-08647-8DOI Listing

ASO Author Reflections: It Is Not a Low-Hanging Fruit: Center Experience Plays an Important Role in Improving Outcomes in Liver Transplantation for Hilar Cholangiocarcinoma.

Ann Surg Oncol 2020 May 26. Epub 2020 May 26.

Division of Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-020-08686-1DOI Listing

Pathologic Doppelgänger: Thyroid-like intrahepatic cholangiocarcinoma with synchronous primary thyroid carcinoma in a young woman.

Ann Hepatobiliary Pancreat Surg 2020 May;24(2):182-187

Department of Surgical Oncology, Tata Memorial Centre, Mumbai, India.

Intrahepatic cholangiocarcinoma (ICC) accounts for 8-10% of all malignant liver tumors. Preponderance for elderly males and occurrence of varied morphological patterns in ICC is well known. Recent reports have described a newly recognized variant of thyroid-like cholangiocarcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14701/ahbps.2020.24.2.182DOI Listing

Right trisectionectomy with en bloc portal vein resection for cholangiocarcinoma after preoperative stenting for main portal vein occlusion.

Ann Hepatobiliary Pancreat Surg 2020 May;24(2):174-181

Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Deprivation of portal blood flow decreases the hepatic function, thus hepatobiliary cancer patients with total occlusion of the main portal vein (PV) are usually not indicated for major hepatectomy. We herein present a 37-year-old male patient with advanced intrahepatic cholangiocarcinoma, in whom right trisectionectomy was indicated. However, the main PV was nearly completely occluded by tumor invasion, thus resolution of jaundice was markedly slow. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14701/ahbps.2020.24.2.174DOI Listing

Impact of Wortmannilactone F and G31P on Clonorchis Sinensis-infected mice.

Int Immunopharmacol 2020 May 23;85:106512. Epub 2020 May 23.

Department of Parasitology, Basic Medical College, Dalian Medical University, Dalian 116044, Liaoning, China. Electronic address:

Clonorchis sinensis could induce inflammation, epithelial hyperplasia and fibrosis in the intrahepatic bile duct as a food-borne parasite, which was associated with the development of cholangiocarcinoma (CCA). Praziquantel was the most effective drug on treatment of this kind of parasite. However, new drugs with minimal toxicity to the host were urgently needed due to the side effects of Praziquantel and its CCA risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.intimp.2020.106512DOI Listing

A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer.

Cancer 2020 May 26. Epub 2020 May 26.

Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida, USA.

Background: Regorafenib is an oral multikinase inhibitor targeting angiogenesis, oncogenesis, and cancer proliferation/metastasis. This study evaluated the efficacy of regorafenib in refractory biliary tract cancer (BTC) in a multi-institutional phase 2 study.

Methods: Patients with BTC who progressed on at least 1 line of systemic therapy received regorafenib at 160 mg daily for 21 days on and 7 days off. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32964DOI Listing

Targeting CLK3 inhibits the progression of cholangiocarcinoma by reprogramming nucleotide metabolism.

J Exp Med 2020 Aug;217(8)

The Affiliated Hospital of Guilin Medical University, Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guangxi Neurological Diseases Clinical Research Center, Guilin, Guangxi, China.

CDC-like kinase 3 (CLK3) is a dual specificity kinase that functions on substrates containing serine/threonine and tyrosine. But its role in human cancer remains unknown. Herein, we demonstrated that CLK3 was significantly up-regulated in cholangiocarcinoma (CCA) and identified a recurrent Q607R somatic substitution that represented a gain-of-function mutation in the CLK3 kinase domain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20191779DOI Listing

Is radical resection of hilar cholangiocarcinoma plus partial resection of pancreatic head justified for advanced hilar cholangiocarcinoma?

ANZ J Surg 2020 May 25. Epub 2020 May 25.

Department of Biliary Surgery, West China Hospital of Sichuan University, Chengdu, China.

Background: To outline our experience with the radical resection of hilar cholangiocarcinoma (HCCA) combined with the partial resection of the pancreatic head (RRHCCAPRPH) as a treatment for HCCA with distal bile duct involvement and to appraise the feasibility of this challenging procedure.

Methods: Between 2007 and 2017, 205 patients with HCCA who underwent curative surgery at our hospital were included. Among the patients, extrahepatic bile duct resection combined with hepatectomy (EBDRH), RRHCCAPRPH and hepatopancreaticoduodenectomy (HPD) was performed in 168, 21 and 16 patients, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ans.15955DOI Listing

WWC1 and NF2 Prevent the Development of Intrahepatic Cholangiocarcinoma by Regulating YAP/TAZ Activity through LATS in Mice.

Mol Cells 2020 May;43(5):491-499

Department of Biological Sciences, National Creative Research Initiatives Center, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea.

Hippo signaling acts as a tumor suppressor pathway by inhibiting the proliferation of adult stem cells and progenitor cells in various organs. Liver-specific deletion of Hippo pathway components in mice induces liver cancer development through activation of the transcriptional coactivators, YAP and TAZ, which exhibit nuclear enrichment and are activated in numerous types of cancer. The upstream-most regulators of Warts, the ortholog of mammalian LATS1/2, are Kibra, Expanded, and Merlin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14348/molcells.2020.0093DOI Listing

[Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis].

Authors:
Dong-Won Ahn

Korean J Gastroenterol 2020 May;75(5):246-256

Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.

Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are immune-mediated chronic liver diseases. PSC is a rare disorder characterized by multi-focal bile duct strictures and progressive liver diseases that ultimately results in the need for liver transplantation in most patients. Imaging studies, such as MRCP, have an essential role in the diagnosis of most cases of PSC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4166/kjg.2020.75.5.246DOI Listing

A Resected Case of Follicular Cholangitis that was Positive on F-fluorodeoxyglucose-Positron Emission Tomography.

Intern Med 2020 May 23. Epub 2020 May 23.

Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Japan.

We experienced a case of follicular cholangitis that was positive on fluorodeoxyglucose-positron emission tomography (F-FDG-PET). A 70-year-old man was admitted for jaundice. Endoscopic retrograde cholangiography showed stenosis of the middle to upper choledocus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.4611-20DOI Listing

Utilization of a new technology of 3D biliary CT for ERCP-related procedures: a case report.

BMC Gastroenterol 2020 May 24;20(1):158. Epub 2020 May 24.

Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Shinkawa 6-20-2, Mitaka-shi, Tokyo, 181-8611, Japan.

Background: Endoscopic retrograde cholangiopancreatography (ERCP) is still performed using two-dimensional (2D) X-ray images. The success rate and risk of complications are considered operator-dependent. We explored performing an ERCP-related procedure with 3D-computed tomography (CT) biliary imaging for preoperative simulation and intraoperative reference in a patient with malignant biliary obstruction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12876-020-01304-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245940PMC

Long non-coding RNA HAGLROS regulates lipid metabolism reprogramming in intrahepatic cholangiocarcinoma via the mTOR signaling pathway.

Exp Mol Pathol 2020 May 21:104466. Epub 2020 May 21.

Department of General Surgery, Minhang Hospital, Fudan University, Shanghai 201100, PR China. Electronic address:

Alternation of long non-coding RNA (lncRNA) is implicated in intrahepatic cholangiocarcinoma (ICC) development. HAGLROS is a lncRNA with a length of 699 bp, which is involved in the progression of various cancers. But the mechanism of HAGLROS in ICC remains unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexmp.2020.104466DOI Listing

Landmark survival analysis and impact of anatomic origin in prospective clinical trials of biliary tract cancer.

J Hepatol 2020 May 21. Epub 2020 May 21.

Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester M20 4BX, UK.

Background: Inclusion of all patients with advanced biliary tract cancer (aBTC), irrespective of anatomic location, in prospective trials, is debated. Survival rates from landmark analysis offer more relevant information once patients have survived for some time.

Aim: assess survival impact of BTC anatomic site origin and landmark survival (LS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2020.05.014DOI Listing

Imaging and Management of Liver Cancer.

Semin Ultrasound CT MR 2020 Apr 14;41(2):122-138. Epub 2019 Dec 14.

University of Toronto, University of Ottawa, Ottawa, Canada. Electronic address:

Imaging of primary hepatic neoplasms in patients at risk for hepatocellular carcinoma (HCC) and in patients with otherwise normal livers relies on proper multiphase image acquisition technique, with emphasis on a high-quality, late arterial phase, using either CT or MRI for accurate image interpretation. The introduction of liver imaging reporting and data system in 2011, with subsequent multiple updates, the most recent in 2018, has provided standardization of image interpretation, reporting and management recommendations for liver observations in patients at risk for HCC. This review article will emphasize key points of imaging primary liver tumors with emphasis on liver imaging reporting and data system, including strengths of this system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.sult.2019.12.002DOI Listing